Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
P10828
UPID:
THB_HUMAN
Alternative names:
Nuclear receptor subfamily 1 group A member 2; c-erbA-2; c-erbA-beta
Alternative UPACC:
P10828; B3KU79; P37243; Q13986; Q3KP35; Q6WGL2; Q9UD41
Background:
Thyroid hormone receptor beta, known as Nuclear receptor subfamily 1 group A member 2, c-erbA-2, or c-erbA-beta, is a pivotal nuclear hormone receptor. It acts as a repressor or activator of transcription with high affinity for thyroid hormones, including triiodothyronine and thyroxine.
Therapeutic significance:
This receptor is implicated in several thyroid hormone resistance syndromes, such as generalized autosomal dominant and recessive thyroid hormone resistance, and selective pituitary thyroid hormone resistance. These conditions highlight the receptor's crucial role in thyroid hormone regulation and its potential as a therapeutic target.